SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Keros Therapeutics appointed Anne Prener, M.D., Ph.D., as a director effective July 1, 2026. Dr. Prener brings significant clinical development and executive leadership experience to the Board. Her compensation package includes initial and annual equity grants totaling $300,000 in grant-date fair value plus a $41,500 annual cash retainer.
View raw filing on EDGAR →Craig Harris was appointed as a director of Kinetik Holdings Inc., effective June 23, 2026, increasing the Board size from 10 to 11 directors. Harris brings 30+ years of energy industry experience and senior leadership roles at Blackstone, Enable Midstream Partners, and El Paso Corporation.
View raw filing on EDGAR →Worthington Steel appointed Gwen Joseph as Corporate Controller and Principal Accounting Officer effective June 23, 2026, with a compensation package of $255,000 base salary, 50% target cash incentive, and $200,000 equity award.
View raw filing on EDGAR →The 6-K discloses the Board's approval on June 22, 2026, of Dr. Cheng Chen's appointment as an independent director, effective immediately. Dr. Chen will also serve on the audit committee, compensation committee, and corporate governance and nominating committee. This is a clear executive/director appointment that would affect a reasonable investor's assessment of the company's governance and board composition.
View raw filing on EDGAR →Sanofi announced the appointment of Paulo Fontoura as Executive Vice President, Global Head of Research & Development Pharma, effective September 1, 2026, with membership on the Executive Committee reporting to the CEO.
View raw filing on EDGAR →Three new directors—Randall Bort, Keith Covington, and Elizabeth Marcellino—were appointed to the board on June 22, 2026, in connection with the company's IPO, with Bort chairing the Audit Committee and Marcellino chairing the Compensation Committee.
View raw filing on EDGAR →The filing discloses two board-level events: the resignation of Sarfraz Maredia on June 17, 2026, and the appointment of Andreas Lieber on June 22, 2026, to fill the vacancy. While both events are disclosed, the principal action emphasized in the Item 5.02 disclosure and press release is the appointment of Lieber, a director with substantial operational and strategic experience (COO of Shippo, interim CEO of Postmates, roles at Uber and Pinterest). The appointment is material to investors as it reflects board composition changes and brings relevant expertise in logistics and platform scaling to a company expanding beyond sidewalk delivery into hospital robotics and infrastructure.
View raw filing on EDGAR →Wilco 63 Corporation appointed four independent directors—James Reynolds, Sriram Ramanathan, Matt Swann, and Joseph Bradley—to its board in connection with the IPO closing on June 22, 2026, with assignments to various board committees under a three-class board structure.
View raw filing on EDGAR →Four directors—R. Greg Smith, Andrew Clark, Harvin Moore, and Aruna Viswanathan—were appointed to the board on June 17, 2026, in connection with the Company's IPO, with assignments to the Audit and Compensation committees.
View raw filing on EDGAR →Mark Fioravanti was appointed as Non-Executive Chairman of the Board effective immediately following the Annual Meeting on June 22, 2026, succeeding Denise W. Warren in the Chairman role.
View raw filing on EDGAR →The exhibit announces Julie Kim's appointment as Representative Director, President and CEO of Takeda following shareholder election and Board approval at the 150th Annual General Meeting. This is a material executive appointment of the company's chief executive officer, the most senior operational role. The disclosure also includes the concurrent retirement of former CEO Christophe Weber and appointments of three new external directors (Broussard, Kimura, Stoffels) and reassignments of existing directors to new committee roles, all effective June 24, 2026.
View raw filing on EDGAR →The filing discloses the appointment of Alex Hastie, Ph.D. as Chief Scientific Officer of Bionano Genomics, effective July 20, 2026. This is a material executive appointment to a senior leadership role responsible for leading the company's global scientific strategy, innovation roadmap, and research initiatives. The appointment is material because it involves a key executive position at a company in the genomics sector where scientific leadership directly impacts competitive positioning and product development strategy.
View raw filing on EDGAR →Richard Fang, Ph.D. was appointed as Interim CEO effective June 18, 2026, following the planned departure of Patrick NJ Schnegelsberg. Dr. Fang will receive an annual salary of $400,000 and brings relevant executive experience to the role.
View raw filing on EDGAR →Ryan Cotterman was appointed as Vice President, Chief Accounting Officer and principal accounting officer of Ingevity Corporation on June 22, 2026. The disclosure centers on the appointment of a named executive officer to a principal accounting role, with detailed compensation terms including base salary ($345,000), bonus target (40%), long-term incentive opportunity (65%), sign-on bonus ($40,000), and equity award ($150,000 RSUs). This is a material executive appointment affecting the registrant's accounting leadership and financial reporting oversight.
View raw filing on EDGAR →Nike announced the appointment of David M. Denton as Executive Vice President and Chief Financial Officer, effective August 17, 2026, replacing Matthew Friend. Denton's compensation package includes a $1.45M base salary, $11.5M long-term incentive target, and a $7.25M new-hire cash award.
View raw filing on EDGAR →F5, Inc. appointed Gavin Munroe as a director effective June 17, 2026, with assignment to the Risk and Audit Committees. The appointment includes compensatory arrangements comprising an annual retainer of $60,000, committee fees of $20,000 each, and a restricted stock unit grant valued at $275,000.
View raw filing on EDGAR →The exhibit announces the appointment of Ms. Qianfei Chang as an independent director, audit committee chairman, and member of two other board committees, effective July 1, 2026. While the disclosure also mentions Mr. Heping Feng's resignation, the principal disclosed action is the appointment of a new director with significant financial and audit expertise to key governance roles. This is material to investors as it affects board composition and oversight functions.
View raw filing on EDGAR →Five new trustees were elected effective as of the company's emergence from bankruptcy: Jonathan Heller, Jonathan Kolatch, William A. Lamkin, Adam D. Portnoy, and Irvin Schlussel. This represents a complete board reconstitution following the Chapter 11 reorganization, with the new trustees assigned to various committees and compensation arrangements.
View raw filing on EDGAR →Bartolomeo A. Frabotta was appointed as Chief Operating Officer of Clean Energy Fuels Corp. effective June 23, 2026, representing a material promotion from his prior role as Group Vice President of Operations. The appointment includes a detailed employment agreement with base salary of $545,056, 100% bonus eligibility, 50,000 RSU equity grants, and severance terms, and makes him a named executive officer.
View raw filing on EDGAR →The filing discloses the election of three new directors to Bank First Corporation's Board of Directors on June 16, 2026: SriRaj Kantamneni, Tracy C. Pearson, and William J. Ring, each for three-year terms. This is a clear executive appointment event involving multiple board-level positions, which is material to investors' assessment of corporate governance and leadership composition.
View raw filing on EDGAR →The Board appointed Daniel M. Skovronsky, M.D., Ph.D., to serve as a director effective June 16, 2026, increasing the Board size from nine to ten members. The disclosure centers on the appointment of a new director with relevant scientific and pharmaceutical R&D expertise, making this a clear exec_appointment event. The appointment is material as it represents a change in the composition of the Board of Directors.
View raw filing on EDGAR →The 6-K announces the appointment of two directors, Mr. Erez Wiener and Mr. Daniel Schutz, effective July 1, 2026. This is a clear executive/governance appointment. The disclosure includes detailed biographical information for both appointees, including Wiener's prior service as CEO of the Company and Schutz's family relationship to the CEO and controlling shareholder Joseph Williger, making this material to investors' assessment of board composition and potential conflicts of interest.
View raw filing on EDGAR →In connection with the merger transaction, Oien was appointed as President and principal executive officer of Boundless Bio, replacing departing CEO Hornby, along with compensatory arrangements including transaction bonuses and acceleration of stock options.
View raw filing on EDGAR →Wendy's appointed Steven W. Cirulis as Chief Financial Officer and Chief Strategy Officer effective June 23, 2026, with a $675,000 base salary, 90% bonus target, and $1,650,000 annualized LTIP grant. Ken Cook departed the CFO role effective July 31, 2026, transitioning to an advisory capacity.
View raw filing on EDGAR →The filing discloses both a departure (James J. Lorenz retiring effective December 31, 2026) and an appointment (John T. Robson appointed Vice President – Energy Operations effective January 1, 2027). While both events are present, the principal forward-looking action and the substantive disclosure centers on the appointment of Robson to succeed Lorenz in a key operational role. The appointment is the material event that addresses continuity of leadership in Energy Operations.
View raw filing on EDGAR →The filing discloses both the departure of Nelson Haight as Executive Vice President and Chief Financial Officer and the appointment of Clinton Roeder to the same role, effective June 22, 2026. While both events are disclosed, the appointment of a new CFO with detailed compensation terms (base salary of $500,000, bonus target of 75%, and equity grants of approximately $500,000) is the forward-looking material event that would affect investor assessment of the company's leadership and financial management going forward. The appointment is the principal action the company is announcing to the market.
View raw filing on EDGAR →The Board appointed W. Bradley Southern as a director effective June 23, 2026, increasing authorized directors from 13 to 14. Mr. Southern brings extensive executive experience as former CEO and Chair of Louisiana-Pacific Corporation (1999–2026) and currently serves as chair of the Nashville Federal Reserve Bank branch.
View raw filing on EDGAR →Cory Anderson was promoted from Senior Vice President, Chief Technology Officer to Executive Vice President, General Manager of Greenbrook effective July 1, 2026. While the disclosure includes compensatory changes (salary increase to $425,000 and bonus target increase to 45%), the principal disclosed action is the promotion to a new executive officer role with expanded responsibilities. The appointment of a person to a higher executive position is the salient event, though the compensation component is secondary.
View raw filing on EDGAR →The filing discloses the appointment of Robert Azelby as a director of Tango Therapeutics, effective June 19, 2026, to fill a newly created board vacancy. While the disclosure also includes compensatory arrangements (equity awards and retainers), the principal action is the appointment itself. The appointment of an experienced biopharmaceutical executive with 30+ years of industry leadership to the board of a clinical-stage biotech company is material to investors assessing the company's governance and strategic direction.
View raw filing on EDGAR →The Board appointed Dr. Robert Wills as non-executive Chair of the Board following the June 16, 2026 annual meeting, a material change to the registrant's senior leadership structure.
View raw filing on EDGAR →The filing discloses the election of Li Shanglong (Michael Li) as new Chairman and the appointment of Shao Weizhi (Eric Shao) as new Chief Executive Officer, following the resignation of James Li from both CEO and Chairman roles. While the filing involves both a departure and appointments, the principal disclosed action centers on the appointment of two new senior executives to lead the company's strategic transformation. The detailed biographical information and Board's rationale for the appointments underscore their materiality to investors assessing leadership continuity and strategic direction.
View raw filing on EDGAR →The 6-K discloses the appointment of Kun Yang as an independent director and member of three board committees, including chair of the Corporate Governance and Nominating Committee, effective June 18, 2026. While the filing also mentions the concurrent resignation of Bin Wu, the principal disclosed action is the appointment of a new director to fill the vacancy. The appointment includes detailed biographical information and confirmation of independence under Nasdaq rules, indicating material governance significance.
View raw filing on EDGAR →The filing discloses the appointment of Jeffrey R. Geygan as a member of Loop Industries' Board of Directors, effective June 22, 2026. The Board increased its size by one seat specifically to accommodate this appointment. While the disclosure also mentions compensatory arrangements (5,170 restricted stock units), the principal disclosed action is the appointment itself, making exec_appointment the most salient classification. Board appointments are material to investors as they affect governance and oversight.
View raw filing on EDGAR →The filing discloses the appointment of Lukas Lutz as an independent director and member of the Nominating and Corporate Governance Committee, effective June 18, 2026, replacing Brian Nelson. The appointment includes a grant of 10,000 RSUs with staggered vesting and standard director compensation, which are material governance changes affecting board composition and leadership structure.
View raw filing on EDGAR →The filing discloses the appointment of Dr. Corazon (Corsee) Sanders to the Board of Directors as a Class III director effective June 17, 2026, and her concurrent appointment to the Audit Committee. The principal disclosed action is a person taking a role. Dr. Sanders is a highly experienced biotechnology executive with 30+ years of leadership at major firms (Genentech/Roche, Juno/Celgene/BMS) and currently serves on multiple public company boards, making her appointment material to investors assessing the company's governance and strategic direction.
View raw filing on EDGAR →The filing discloses the appointment of Kevin Miller as Executive Vice President, Chief Financial Officer and Treasurer, effective June 1, 2026, with an employment agreement dated June 18, 2026. While the agreement includes detailed compensation terms (base salary of $430,000, bonus eligibility, and equity awards), the principal disclosed action is the appointment of a named executive officer to a C-suite position. This is material to investors as it represents a significant leadership change in the company's financial management.
View raw filing on EDGAR →Wayne Tupuola, the President and CEO, took a three-month leave of absence for health reasons on June 16, 2026, and the Board appointed Ann Tewari, Executive Vice President of Global Operations and Strategy, as Interim President. While the filing discloses both a departure (Tupuola's leave) and an appointment (Tewari's interim role), the principal disclosed action centers on the appointment of interim leadership to fill the CEO vacancy during Tupuola's absence. This is material as it affects the registrant's executive leadership structure and investor assessment of operational continuity.
View raw filing on EDGAR →Robert Brackenbury was appointed to the Board of Directors of Athene Holding Ltd. as an independent director effective June 23, 2026. Brackenbury brings extensive experience as Deputy Chief Investment Officer of the State of Michigan Retirement System, where he oversaw $170 billion in assets, and brings expertise in retirement services and institutional investment management.
View raw filing on EDGAR →The filing discloses the appointment of Ron Philip to the Board of Directors of Avalo Therapeutics, effective June 23, 2026. The principal disclosed action is a person taking a role as director and committee member. While the disclosure includes compensatory arrangements (stock option grant of 40,200 shares), the core event is the appointment itself, making exec_appointment the most salient classification. Board appointments by experienced executives (Philip's background includes CEO roles at Spark Therapeutics and Orbital Therapeutics) are material to investors.
View raw filing on EDGAR →Cal-Maine Foods appointed two independent directors, Haley R. Fisackerly and Michael J. Highfield, to its Board of Directors effective June 23, 2026, expanding the Board from eight to ten directors. The new directors bring expertise in operations, infrastructure, finance, capital markets, and organizational leadership, and were assigned to three Board committees.
View raw filing on EDGAR →Adriano Duarte was appointed Executive Vice President and Chief Financial Officer of Provident Financial Services, Inc. and Provident Bank, effective July 1, 2026. Duarte brings over 30 years of banking experience and previously served as Chief Accounting Officer, and will report directly to the CEO and serve on the Executive Leadership Team.
View raw filing on EDGAR →Ferrari announces the appointment of Massimiliano Di Silvestre as Chief Marketing & Commercial Officer effective July 1, 2026, joining the Leadership Team and reporting to CEO Benedetto Vigna. While the announcement also mentions Enrico Galliera's departure after sixteen years, the principal disclosed action is the appointment of a named executive to a C-suite role. This is material as it affects the composition of Ferrari's senior leadership and the company's strategic direction in marketing and commercial operations.
View raw filing on EDGAR →The filing discloses the appointment of Moncef Slaoui to the Board as a Class II director effective immediately on June 17, 2026, upon recommendation of the Nominating and Corporate Governance Committee. While the section also mentions Jacks Lee's retirement from the Board and his entry into a consulting agreement, the principal disclosed action centers on the new director appointment. Board composition changes are material to investors' assessment of governance and strategic direction.
View raw filing on EDGAR →The exhibit announces the appointment of R. Lynn Atchison to Einride's Board of Directors, subject to shareholder and regulatory approvals. This is a clear executive/governance appointment of a seasoned public company director and financial executive with extensive experience at high-growth technology companies and prior CFO roles. The appointment is material given Atchison's deep expertise, her current board positions at public companies (Bumble, Q2 Holdings), and the company's recent Nasdaq listing, which makes board composition particularly relevant to public market investors.
View raw filing on EDGAR →The Board appointed Adeel Rouf to serve as an independent director and Audit Committee member, effective immediately on June 22, 2026. This is a clear executive appointment under Item 5.02, with detailed disclosure of his qualifications and prior experience in financial services and SPAC transactions. The appointment of a director to a public company's board, particularly to the Audit Committee, is material to investors assessing governance and oversight.
View raw filing on EDGAR →QuidelOrtho appointed Micah Young as Chief Financial Officer effective July 6, 2026, succeeding retiring CFO Joseph M. Busky. Young brings extensive experience from Masimo, NuVasive, and Zimmer Holdings, with a compensation package including a $750,000 base salary, $500,000 sign-on bonus, $6.5M inducement RSU grant, and $5M expected 2027 equity grant.
View raw filing on EDGAR →Roy E. Halyama was appointed President of Burke & Herbert Financial Services Corp. and Burke & Herbert Bank & Trust Company effective July 1, 2026, following the previously announced retirement of H. Charles Maddy, III. While the disclosure mentions both the appointment and the departure, the principal disclosed action centers on Halyama taking the President role—a material executive appointment at a financial services company. The filing explicitly states "No modifications to Mr. Halyama's compensation arrangements were made in connection with his appointment," confirming this is an appointment event rather than a compensation event.
View raw filing on EDGAR →Cincinnati Financial Corporation appointed Lisa M. Franchetti, a retired Admiral and former Chief of Naval Operations (2023–2025), to its board of directors and audit committee, effective immediately, expanding the board to 15 seats.
View raw filing on EDGAR →The news release announces the appointment of Edwin Shadeo as Acting Vice President, Investor Relations and Treasurer, effective immediately. While the release also mentions Emma Chapman's departure, the principal disclosed action is Shadeo's appointment to a named executive officer role. The appointment of a VP-level officer with treasury and investor relations responsibilities is material to a reasonable investor's assessment of the company's leadership and capital markets engagement.
View raw filing on EDGAR →Lauren M. Tyler was elected to Centene's Board of Directors effective June 19, 2026, filling a newly created vacancy as the Board expanded from 9 to 10 members. She was assigned to the Audit Committee and Compensation and Talent Committee, bringing 30+ years of leadership experience including senior roles at JPMorgan Chase and current board service at Cencora and Guardian Life.
View raw filing on EDGAR →